Study the Effect of Polycystic Ovarian Syndrome on the Ferriman-Gallwey Score and Some Anthropometric and Demographic Criteria on Women in Al-Ramadi City
DOI:
https://doi.org/10.31185/wjps.438Keywords:
polycystic ovarian syndrom, Ferriman-Gallwey score, anthropometric and demographic criteriaAbstract
Introduction: Polycystic ovarian syndrome (PCOS) is one of the most common complex endocrine disorders that affect females at the reproductive age, can cause obesity, the appearance of excess hair on the body, acne, menstrual irregularities and infertility.
Aim: This study aimed to identify the extent to which some anthropometric and demographic criteria are affected by PCOS compared to healthy women
Method: The study included 50 volunteer women divided into two groups, the first group included 25 women with polycystic ovarian syndrome, and 25 healthy women were considered as a control group, women treated with medication and those with other diseases were excluded.
Result: The current study found that there was a significant increase in body mass index BMI for women with PCOS compared with the control group. It also found that there was a significant increase in Ferriman-Gallwey score as a measure of hirsutism, in the patient group compared to the control group of .
The study also found that the rate of infertility was closely associated with polycystic ovarian syndrome, also confirmed that there was a significant increase in women suffering from menstrual irregularities compared with control group, while the family history of the disease had no influence on the development of the disease in the study sample.
Conclusion: We observed that obesity and hirsutism are associated with a polycystic ovarian syndrom, and polycystic ovarian syndrome can lead to menstrual irregularities, which usually ends with infertility.
References
REFERENCES
N. F. Goodman, R. H. Cobin, W. Futterweit, J. S. Glueck, R. S. Legro, and E. Carmina, “American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 1,” Endocr. Pract., vol. 21, no. 11, pp. 1291–1300, 2015, doi: 10.4158/EP15748.DSC.
R. Wang and B. W. J. Mol, “The Rotterdam criteria for polycystic ovary syndrome: Evidence-based criteria?,” Hum. Reprod., vol. 32, no. 2, pp. 261–264, 2017, doi: 10.1093/humrep/dew287.
G. J. Ferriman David, “Clinical assessment of body hair in women.,” J Clin Endocrinol Meta., vol. 21, no. January, pp. 1440–7, 1961.
P. M. Spritzer, L. B. Marchesan, B. R. Santos, and T. M. Fighera, “Hirsutism, Normal Androgens and Diagnosis of PCOS,” Diagnostics, vol. 12, no. 8, pp. 1–12, 2022, doi: 10.3390/diagnostics12081922.
M. Giammanco, L. Lantieri, G. Leto, F. Plescia, and D. Di Majo, “Nutrition, obesity and hormones,” J. Biol. Res., vol. 91, no. 2, pp. 108–118, 2018, doi: 10.4081/jbr.2018.7755.
R. C. Weisell, “Body mass index as an indicator of obesity,” Asia Pac. J. Clin. Nutr., vol. 11, no. s8, 2002, doi: 10.1046/j.1440-6047.11.s8.5.x.
P. Saxena, A. Prakash, A. Nigam, and A. Mishra, “Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index,” Indian J. Endocrinol. Metab., vol. 16, no. 6, p. 996, 2012, doi: 10.4103/2230-8210.103011.
A. Kabel, “Polycystic Ovarian Syndrome : Insights into Pathogenesis , Diagnosis ,” Pathog. Pcos, vol. 1, no. 1, pp. 1–5, 2016.
R. Pray and S. Riskin, “The History and Faults of the Body Mass Index and Where to Look Next: A Literature Review,” Cureus, vol. 15, no. 11, 2023, doi: 10.7759/cureus.48230.
J. H. Kim, O. Kim, H. Jung, Y. Pang, and H. Dan, “Body mass index, menstruation, acne, and hirsutism of polycystic ovary syndrome in women: A cross-sectional study,” Health Care Women Int., vol. 43, no. 1–3, pp. 85–97, 2022, doi: 10.1080/07399332.2021.1939348.
N. Jalilian, L. Haghnazari, and S. Rasolinia, “Leptin and body mass index in polycystic ovary syndrome,” Indian J. Endocrinol. Metab., vol. 20, no. 3, pp. 324–328, 2016, doi: 10.4103/2230-8210.180005.
H. F. Escobar-Morreale et al., “Epidemiology, diagnosis and management of hirsutism: A consensus statement by the androgen excess and polycystic ovary syndrome society,” Hum. Reprod. Update, vol. 18, no. 2, pp. 146–170, 2012, doi: 10.1093/humupd/dmr042.
P. Spritzer, C. Barone, and F. Oliveira, “Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management,” Curr. Pharm. Des., vol. 22, no. 36, pp. 5603–5613, 2016, doi: 10.2174/1381612822666160720151243.
S. A. Neubronner, I. R. Indran, Y. H. Chan, A. W. P. Thu, and E. L. Yong, “Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study,” BMC Womens. Health, vol. 21, no. 1, pp. 1–12, 2021, doi: 10.1186/s12905-021-01277-6.
A. N. Schüring, N. Schulte, B. Sonntag, and L. Kiesel, “Androgens and insulin - Two key players in polycystic ovary syndrome: Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome,” Gynakol. Geburtshilfliche. Rundsch., vol. 48, no. 1, pp. 9–15, 2008, doi: 10.1159/000111465.
O. Valkenburg et al., “A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: A case-control study,” J. Clin. Endocrinol. Metab., vol. 93, no. 2, pp. 470–476, 2008, doi: 10.1210/jc.2007-1756.
S. E. Recabarren et al., “Metabolic profile in sons of women with polycystic ovary syndrome,” J. Clin. Endocrinol. Metab., vol. 93, no. 5, pp. 1820–1826, 2008, doi: 10.1210/jc.2007-2256.
M. M. Huber-Buchholz, D. G. P. Carey, and R. J. Norman, “Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone,” J. Clin. Endocrinol. Metab., vol. 84, no. 4, pp. 1470–1474, 1999, doi: 10.1210/jc.84.4.1470.
L. J. Moran, M. Noakes, P. M. Clifton, L. Tomlinson, and R. J. Norman, “Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome,” J. Clin. Endocrinol. Metab., vol. 88, no. 2, pp. 812–819, 2003, doi: 10.1210/jc.2002-020815.
A. Mofid, S. A. Seyyed Alinaghi, S. Zandieh, and T. Yazdani, “Hirsutism,” Int. J. Clin. Pract., vol. 62, no. 3, pp. 433–443, 2008, doi: 10.1111/j.1742-1241.2007.01621.x.
H. D. McClamrock and E. Y. Adashi, “Polycystic ovarian syndrome and associated hirsutism in the adolescent,” Adolesc. Pediatr. Gynecol., vol. 5, no. 4, pp. 231–241, 1992, doi: 10.1016/S0932-8610(19)80155-X.
M. J. Khan, A. Ullah, and S. Basit, “Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives,” Appl. Clin. Genet., vol. 12, pp. 249–260, 2019, doi: 10.2147/TACG.S200341.
S. Singh et al., “Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics,” J. Clin. Med., vol. 12, no. 4, 2023, doi: 10.3390/jcm12041454.
R. Kumar et al., “Role of genetic, environmental, and hormonal factors in the progression of PCOS: A review,” J. Reprod. Healthc. Med., vol. 3, no. 3, p. 3, 2022, doi: 10.25259/jrhm_16_2021.
E. Kandaraki et al., “Endocrine disruptors and Polycystic Ovary Syndrome (PCOS): Elevated serum levels of bisphenol A in women with PCOS,” J. Clin. Endocrinol. Metab., vol. 96, no. 3, pp. 480–484, 2011, doi: 10.1210/jc.2010-1658.
T. Takeuchi, O. Tsutsumi, Y. Ikezuki, Y. Takai, and Y. Taketani, “Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction,” Endocr. J., vol. 51, no. 2, pp. 165–169, 2004, doi: 10.1507/endocrj.51.165.
A. Konieczna et al., “Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome,” Reprod. Toxicol., vol. 82, pp. 32–37, 2018, doi: 10.1016/j.reprotox.2018.09.006.
M. Kazemi, A. Hadi, R. A. Pierson, M. E. Lujan, G. A. Zello, and P. D. Chilibeck, “Effects of Dietary Glycemic Index and Glycemic Load on Cardiometabolic and Reproductive Profiles in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials,” Adv. Nutr., vol. 12, no. 1, pp. 161–178, 2021, doi: 10.1093/advances/nmaa092.
M. Szczuko, M. Skowronek, M. Zapałowska-Chwyć, and A. Starczewski, “Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS),” Rocz. Panstw. Zakl. Hig., vol. 67, no. 4, pp. 419–426, 2016.
M. G. Rizk and V. G. Thackray, “Intersection of polycystic ovary syndrome and the gut microbiome,” J. Endocr. Soc., vol. 5, no. 2, pp. 1–16, 2021, doi: 10.1210/jendso/bvaa177.
C. Kshetrimayum, A. Sharma, V. V. Mishra, and S. Kumar, “Polycystic ovarian syndrome: Environmental/ occupational, lifestyle factors; an overview,” J. Turkish Ger. Gynecol. Assoc., vol. 20, no. 4, pp. 255–263, 2019, doi: 10.4274/jtgga.galenos.2019.2018.0142.
G. Yurtdaş and Y. Akdevelioğlu, “A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota,” J. Am. Coll. Nutr., vol. 39, no. 4, pp. 371–382, 2020, doi: 10.1080/07315724.2019.1657515.
R. Liu et al., “Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome,” Front. Microbiol., vol. 8, no. FEB, pp. 1–12, 2017, doi: 10.3389/fmicb.2017.00324.
K. Tremellen and K. Pearce, “Dysbiosis of Gut Microbiota (DOGMA) - A novel theory for the development of Polycystic Ovarian Syndrome,” Med. Hypotheses, vol. 79, no. 1, pp. 104–112, 2012, doi: 10.1016/j.mehy.2012.04.016.
H. R. Harris, L. J. Titus, D. W. Cramer, and K. L. Terry, “Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study,” Int. J. Cancer, vol. 140, no. 2, pp. 285–291, 2017, doi: 10.1002/ijc.30441.
S. West et al., “Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study,” Hum. Reprod., vol. 29, no. 10, pp. 2339–2351, 2014, doi: 10.1093/humrep/deu200.
V. Christodoulopoulou et al., “Clinical and Biochemical Characteristics in PCOS Women With Menstrual Abnormalities.,” J. Fam. Reprod. Heal., vol. 10, no. 4, pp. 184–190, 2016, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/28546817%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5440817
J. A. Barry, M. M. Azizia, and P. J. Hardiman, “Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis,” Hum. Reprod. Update, vol. 20, no. 5, pp. 748–758, 2014, doi: 10.1093/humupd/dmu012.
Z. Xue et al., “Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium,” Front. Physiol., vol. 12, no. December, 2021, doi: 10.3389/fphys.2021.788772.
A. S. Melo, R. A. Ferriani, and P. A. Navarro, “Treatment of infertility in women with polycystic ovary syndrome: Approach to clinical practice,” Clinics, vol. 70, no. 11, pp. 765–769, 2015, doi: 10.6061/clinics/2015(11)09.
A. D. Anderson, C. M. B. Solorzano, and C. R. McCartney, “Childhood obesity and its impact on the development of adolescent PCOS,” Semin. Reprod. Med., vol. 32, no. 3, pp. 202–213, 2014, doi: 10.1055/s-0034-1371092.
M. Li, X. Ruan, and A. O. Mueck, “Management strategy of infertility in polycystic ovary syndrome,” Glob. Heal. J., vol. 6, no. 2, pp. 70–74, 2022, doi: 10.1016/j.glohj.2022.03.002.
C. C. Dennett and J. Simon, “The role of polycystic ovary syndrome in reproductive and metabolic health: Overview and approaches for treatment,” Diabetes Spectr., vol. 28, no. 2, pp. 116–120, 2015, doi: 10.2337/diaspect.28.2.116.
J. Collée, M. Mawet, L. Tebache, M. Nisolle, and G. Brichant, “Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments,” Gynecol. Endocrinol., vol. 37, no. 10, pp. 869–874, 2021, doi: 10.1080/09513590.2021.1958310.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Zaman Nazar Hameed Al - anii
This work is licensed under a Creative Commons Attribution 4.0 International License.
